Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib

Matthew J Wongchenko; Antoni Ribas; Brigitte Dréno; Paolo A Ascierto; Grant A McArthur; Jorge D Gallo; Isabelle A Rooney; Jessie Hsu; Hartmut Koeppen; Yibing Yan; James Larkin

doi:10.1111/pcmr.12670

Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib

Matthew J Wongchenko, Antoni Ribas, Brigitte Dréno, Paolo A Ascierto, Grant A McArthur, Jorge D Gallo, Isabelle A Rooney, Jessie Hsu, Hartmut Koeppen, Yibing Yan, James Larkin

Istituto Nazionale Tumori Fondazione G. Pascale

Research output: Contribution to journal › Article › peer-review

Abstract

The prognostic significance of programmed death ligand-1 (PD-L1) on treatment outcomes in patients receiving BRAF with or without MEK inhibitors is not well understood. This retrospective exploratory analysis evaluated the association of tumour PD-L1 expression with progression-free survival (PFS) and overall survival (OS) among 210 patients in the coBRIM trial treated with cobimetinib plus vemurafenib or placebo plus vemurafenib. In the vemurafenib cohort, there was a trend of increased PFS and OS in those with PD-L1+ melanoma, with hazard ratios (HRs; PD-L1+ vs. PD-L1- ) of 0.70 (95% CI, 0.46-1.07) and 0.69 (95% CI, 0.42-1.13) for PFS and OS, respectively. However, in patients treated with cobimetinib plus vemurafenib, a similar trend was not observed with HRs (PD-L1+ versus PD-L1- ) of 1.04 (95% CI, 0.66-1.68) and 0.94 (95% CI, 0.57-1.57) for PFS and OS, respectively. The combination cobimetinib plus vemurafenib appears to overcome the poor prognosis associated with low PD-L1 expression.

Original language	English
Pages (from-to)	516-522
Number of pages	7
Journal	Pigment Cell and Melanoma Research
Volume	31
Issue number	4
DOIs	https://doi.org/10.1111/pcmr.12670
Publication status	Published - Jul 2018

Access to Document

10.1111/pcmr.12670

Cite this

Wongchenko, M. J., Ribas, A., Dréno, B., Ascierto, P. A., McArthur, G. A., Gallo, J. D., Rooney, I. A., Hsu, J., Koeppen, H., Yan, Y., & Larkin, J. (2018). Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib. Pigment Cell and Melanoma Research, 31(4), 516-522. https://doi.org/10.1111/pcmr.12670

Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib. / Wongchenko, Matthew J; Ribas, Antoni; Dréno, Brigitte et al.

In: Pigment Cell and Melanoma Research, Vol. 31, No. 4, 07.2018, p. 516-522.

Research output: Contribution to journal › Article › peer-review

Wongchenko, MJ, Ribas, A, Dréno, B, Ascierto, PA, McArthur, GA, Gallo, JD, Rooney, IA, Hsu, J, Koeppen, H, Yan, Y & Larkin, J 2018, 'Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib', Pigment Cell and Melanoma Research, vol. 31, no. 4, pp. 516-522. https://doi.org/10.1111/pcmr.12670

@article{1c4d999f7673450ea05fe473be9d7ef4,

title = "Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib",

abstract = "The prognostic significance of programmed death ligand-1 (PD-L1) on treatment outcomes in patients receiving BRAF with or without MEK inhibitors is not well understood. This retrospective exploratory analysis evaluated the association of tumour PD-L1 expression with progression-free survival (PFS) and overall survival (OS) among 210 patients in the coBRIM trial treated with cobimetinib plus vemurafenib or placebo plus vemurafenib. In the vemurafenib cohort, there was a trend of increased PFS and OS in those with PD-L1+ melanoma, with hazard ratios (HRs; PD-L1+ vs. PD-L1- ) of 0.70 (95% CI, 0.46-1.07) and 0.69 (95% CI, 0.42-1.13) for PFS and OS, respectively. However, in patients treated with cobimetinib plus vemurafenib, a similar trend was not observed with HRs (PD-L1+ versus PD-L1- ) of 1.04 (95% CI, 0.66-1.68) and 0.94 (95% CI, 0.57-1.57) for PFS and OS, respectively. The combination cobimetinib plus vemurafenib appears to overcome the poor prognosis associated with low PD-L1 expression.",

author = "Wongchenko, {Matthew J} and Antoni Ribas and Brigitte Dr{\'e}no and Ascierto, {Paolo A} and McArthur, {Grant A} and Gallo, {Jorge D} and Rooney, {Isabelle A} and Jessie Hsu and Hartmut Koeppen and Yibing Yan and James Larkin",

note = "{\textcopyright} 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.",

year = "2018",

month = jul,

doi = "10.1111/pcmr.12670",

language = "English",

volume = "31",

pages = "516--522",

journal = "Pigment Cell and Melanoma Research",

issn = "1755-1471",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib

AU - Wongchenko, Matthew J

AU - Ribas, Antoni

AU - Dréno, Brigitte

AU - Ascierto, Paolo A

AU - McArthur, Grant A

AU - Gallo, Jorge D

AU - Rooney, Isabelle A

AU - Hsu, Jessie

AU - Koeppen, Hartmut

AU - Yan, Yibing

AU - Larkin, James

PY - 2018/7

Y1 - 2018/7

N2 - The prognostic significance of programmed death ligand-1 (PD-L1) on treatment outcomes in patients receiving BRAF with or without MEK inhibitors is not well understood. This retrospective exploratory analysis evaluated the association of tumour PD-L1 expression with progression-free survival (PFS) and overall survival (OS) among 210 patients in the coBRIM trial treated with cobimetinib plus vemurafenib or placebo plus vemurafenib. In the vemurafenib cohort, there was a trend of increased PFS and OS in those with PD-L1+ melanoma, with hazard ratios (HRs; PD-L1+ vs. PD-L1- ) of 0.70 (95% CI, 0.46-1.07) and 0.69 (95% CI, 0.42-1.13) for PFS and OS, respectively. However, in patients treated with cobimetinib plus vemurafenib, a similar trend was not observed with HRs (PD-L1+ versus PD-L1- ) of 1.04 (95% CI, 0.66-1.68) and 0.94 (95% CI, 0.57-1.57) for PFS and OS, respectively. The combination cobimetinib plus vemurafenib appears to overcome the poor prognosis associated with low PD-L1 expression.

AB - The prognostic significance of programmed death ligand-1 (PD-L1) on treatment outcomes in patients receiving BRAF with or without MEK inhibitors is not well understood. This retrospective exploratory analysis evaluated the association of tumour PD-L1 expression with progression-free survival (PFS) and overall survival (OS) among 210 patients in the coBRIM trial treated with cobimetinib plus vemurafenib or placebo plus vemurafenib. In the vemurafenib cohort, there was a trend of increased PFS and OS in those with PD-L1+ melanoma, with hazard ratios (HRs; PD-L1+ vs. PD-L1- ) of 0.70 (95% CI, 0.46-1.07) and 0.69 (95% CI, 0.42-1.13) for PFS and OS, respectively. However, in patients treated with cobimetinib plus vemurafenib, a similar trend was not observed with HRs (PD-L1+ versus PD-L1- ) of 1.04 (95% CI, 0.66-1.68) and 0.94 (95% CI, 0.57-1.57) for PFS and OS, respectively. The combination cobimetinib plus vemurafenib appears to overcome the poor prognosis associated with low PD-L1 expression.

U2 - 10.1111/pcmr.12670

DO - 10.1111/pcmr.12670

M3 - Article

C2 - 29156488

VL - 31

SP - 516

EP - 522

JO - Pigment Cell and Melanoma Research

JF - Pigment Cell and Melanoma Research

SN - 1755-1471

IS - 4

ER -

Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib

Abstract

Access to Document

Fingerprint

Cite this